Heavy periods: how menstrual blood could transform diagnosis

Heavy periods are common, disruptive and still too often investigated through indirect measures. Blood tests can identify anaemia, scans can reveal fibroids or adenomyosis, and symptom histories can establish how bleeding affects daily life. Yet the fluid produced during menstruation has rarely been treated as a serious source of biological information.

That may be changing. A project reported by BBC Health aims to create the world’s largest menstrual fluid biobank, while saliva-based testing for endometriosis is also entering trials. Together, these developments point to a broader shift in cycle science: researchers are looking for biomarkers in samples that are easier to collect and more closely connected to reproductive biology. The promise is substantial, but neither approach is ready to replace a full clinical assessment.

Why heavy periods remain difficult to measure

Heavy menstrual bleeding is not defined only by a precise volume of blood. In clinical practice, its effect on physical health, quality of life and normal activity matters. Bleeding that requires very frequent product changes, continues for more than about a week, causes flooding or large clots, or contributes to iron deficiency warrants attention even when the exact volume is unknown.

The causes are varied. Fibroids, adenomyosis, endometriosis, ovulatory disruption, bleeding disorders, some medicines and certain contraceptive devices can contribute. Perimenopause can bring less predictable ovulation and changes in flow. Sometimes no clear structural cause is found.

This variability creates a measurement problem. A single blood count can show the consequence of repeated blood loss, but not necessarily its cause. Ultrasound is useful for some structural conditions, yet normal imaging does not exclude endometriosis or every source of abnormal bleeding. Symptom recall can also be imprecise, particularly when cycle changes develop gradually.

Better biomarkers could help separate biological subtypes that currently sit under the same broad symptom label. That distinction matters because treatments for fibroids, a coagulation problem and ovulatory bleeding are not interchangeable.

What menstrual blood may reveal

Menstrual fluid is biologically complex. It contains peripheral blood alongside endometrial cells, immune cells, tissue fragments, proteins and other molecules involved in the monthly breakdown and repair of the uterine lining. In principle, that makes it a direct window into processes that standard blood tests may capture only weakly.

A large biobank could allow researchers to compare samples from people with and without heavy bleeding, then examine how molecular patterns differ by diagnosis, age, cycle characteristics, medication use and treatment response. Scale is important. Small studies can generate promising signals, but diverse, well-characterised samples are needed to determine whether a marker is reproducible and clinically useful.

The project could also improve understanding of normal variation. Menstrual flow and symptoms differ between people and across cycles. Without robust reference data, a biological difference can be difficult to interpret. A biobank linked to detailed clinical information may help distinguish a stable disease signal from ordinary cycle-to-cycle fluctuation.

Collection methods will matter. Samples can vary according to the day of bleeding, collection product, storage time, contamination and recent hormonal treatment. Researchers will need standardised protocols and validation across populations. A statistically detectable marker is not automatically an accurate diagnostic test.

Heavy periods, endometriosis and the search for accessible tests

The renewed interest in menstrual samples sits alongside trials of a saliva test for endometriosis. Endometriosis can take years to diagnose because symptoms overlap with other conditions, lesions are not always visible on routine imaging, and definitive assessment may require specialist expertise or surgery.

A non-invasive test could potentially shorten that process, but early test performance must be interpreted carefully. Accuracy reported in a selected research group may fall when the test is used among people with mixed symptoms in routine care. Researchers need to establish sensitivity, specificity, false-positive rates and performance across different disease stages and hormonal states.

Menstrual fluid and saliva answer slightly different scientific questions. Menstrual material may contain signals local to the endometrium and reproductive tract. Saliva is simpler to collect and may contain systemic molecular patterns associated with disease. Neither sample is inherently superior. Clinical value depends on whether a test meaningfully changes diagnosis or treatment beyond symptom assessment, examination, imaging and existing laboratory work.

There is also unlikely to be one biomarker that explains every painful or heavy cycle. Endometriosis itself is heterogeneous, and heavy bleeding may arise from several overlapping conditions. The more realistic future may be a panel of markers combined with cycle history, iron status, imaging and other clinical information.

What this means for care now

These projects do not make current evaluation obsolete. Persistent heavy bleeding can deplete iron before haemoglobin falls enough to meet the threshold for anaemia, so ferritin and a full blood count may both be relevant. A clinician may also consider pregnancy, thyroid function, medications, contraception, inherited bleeding tendencies and structural uterine causes, depending on the pattern and context.

Bleeding after menopause, bleeding between periods, or a marked change from an established pattern requires medical assessment. Urgent care may be appropriate when bleeding is accompanied by fainting, severe weakness, breathlessness, intense pain or possible pregnancy. New biomarkers may eventually refine these pathways, but they are not yet substitutes for them.

The larger advance is conceptual. Menstrual blood has often been discarded both literally and scientifically, despite coming from tissue central to reproductive health. Treating it as a research sample could produce more female-specific evidence and make menstrual symptoms biologically legible rather than relying on retrospective descriptions alone.

That evidence will be strongest when laboratory findings are connected to longitudinal cycle data. Bleeding duration, flow pattern, pain, fatigue and related cycle symptoms only become readable when logged consistently over weeks, and this is the kind of pattern Tulsy is built to surface.

Sources: BBC Health, Medical Xpress.

This content is for informational and educational purposes only. It is not intended to diagnose, treat, cure, or prevent any disease, and should not replace advice from a qualified healthcare professional.